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Abstract

Objective This study investigated the effects of the
inflammatory tissue response (ITR) to an insulin infusion
set (IIS) on insulin bolus spread over wear time, as well
as the effect of cannula insertion angle on the ITR, bolus
shape, and pump tubing pressure.
Research design and methods Angled or straight
IISs were inserted every other day for 14 days into
the subcutaneous tissue of 11 swine and insulin was
delivered continuously. Prior to euthanasia, a 70 µL bolus
of insulin/X-ray contrast agent was infused while recording
a pressure profile (peak tubing pressure, pmax; area under
the pressure curve, AUC), followed by the excision of
the tissue-catheter specimen. Bolus surface area (SA)
and volume (V) were assessed via micro-CT. Tissue was
stained to analyze total area of inflammation (TAI) and
inflammatory layer thickness (ILT) surrounding the cannula.
Results A bolus delivered through an angled IIS had
a larger mean SA than a bolus delivered through a
straight cannula (314.0±84.2 mm2 vs 229.0±99.7 mm2,
p<0.001) and a larger volume (198.7±66.9 mm3 vs
145.0±65.9 mm3, p=0.001). Both decreased significantly
over wear time, independent of angle. There was a
significant difference in TAI (angled, 9.1±4.0 mm2 vs
straight, 14.3±8.6 mm2, p<0.001) and ILT (angled,
0.7±0.4 vs straight, 1.2±0.7 mm, p<0.001). pmax (p=0.005)
and AUC (p=0.014) were lower using angled IIS. As ILT
increased, pmax increased, while SA and V decreased.
Conclusions The progression of the ITR directly affected
bolus shape and tubing pressure. Although straight
insertion is clinically preferred, our data suggest that
an angled IIS elicits lower grades of ITR and delivers a
bolus with lower tubing pressure and greater SA and V.
The subcutaneous environment plays a crucial role in IIS
longevity, and the insertion angle needs to be considered in
future IIS designs and clinical trials.

Introduction
The number of patients with type 1 and
type 2 diabetes worldwide using continuous

Significance of this study
What is already known about this subject?
►► The variability of insulin absorption increases over

infusion set wear time and it may be attributed to the
inflammatory tissue response.

What are the new findings?
►► As the inflammatory tissue response progresses

over infusion set wear time, the bolus volume and
bolus surface area decrease, and this effect is diminished using angled insulin infusion catheters
instead of straight infusion sets.

How might these results change the focus of
research or clinical practice?
►► The angle of insertion needs to be considered in

future insulin infusion set design and clinical trials.

subcutaneous insulin infusion (CSII) therapy
to manage their blood glucose (BG) levels
loop and hybrid closed-
is rising.1 Closed-
loop automated insulin delivery systems
have become accessible and show promising
results by improving BG control, decreasing
the incidence of hypoglycemia, and alleviating some of the burden of the disease.2–4
The weak link in the success of insulin pump
therapy and artificial pancreas systems is still
the insulin infusion set (IIS), in particular the
cannula residing in the subcutaneous tissue
of the patient. Manufacturers, regulators, and
professional societies currently recommend
changing a commercial Teflon IIS every 2–3
days due to an increase in insulin absorption variability and therefore worsening
of glycemic control.5 6 An ideal IIS would
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produce rapid and consistent absorption of insulin from
the subcutaneous tissue into the bloodstream from dose-
to-dose and day-to-day for more than 7 days, and minimize the formation of scar tissue that may adversely affect
insulin absorption and future pump use.
It is debated whether a clinical difference exists
between CSII catheters inserted at 90° compared with
angled insertions (typically 30°–45°).7 8 A 90° (straight)
IIS is generally preferred by patients due to its easier
method of insertion, especially when teaching children
or patients with poor dexterity.8 9 However, especially in
slim patients, the risk of intramuscular injection is greater
when inserting at 90°, which increases the incidence of
cannula kinking, occlusion, insertion pain and hypoglycemia.7 10 It has been reported that using angled IIS
reduces the risk of cannula kinking and dislodgment.8 9 11
Although an increasing number of patients use Teflon
IIS every day, there is a lack of systematic in vivo studies
on the impact of angle of insertion on the subcutaneous
inflammatory tissue response and the pattern of insulin
delivery over time.
We have previously reported that the inflammatory
response to the cannula of an IIS and insulin/preservatives can have a significant effect on insulin absorption
(pharmacokinetics).12 In the present study, we combined
micro-
CT imaging, histopathology and insulin tubing
pressure analysis to investigate the progression of the
inflammatory tissue response to straight and angled CSII
catheters over time in a non-diabetic swine model. This
animal model has been successfully used in prior studies
by our group and collaborators,12 13 and has been shown
to be the most adequate for human skin and adipose
tissue wound healing.14 We hypothesized that the change
in thickness of the layer of acute and chronic inflammatory tissue surrounding the cannula of a CSII catheter
has a direct effect on insulin spread (bolus volume and
surface area) and tubing pressure. We further hypothesized that the angle of insertion (90° vs 30°) would significantly affect the total area of inflammation, the thickness
of the inflammatory layer surrounding the cannula, the
bolus surface area, bolus volume, and pump tubing pressure during an insulin bolus.
Research design and methods
Eleven healthy Yorkshire female swine, aged 3–6 months
and weighing 60–70 kg, were used as a model of human
subcutaneous tissue.14 15 Female swine were chosen over
male animals due to their larger abdominal surface area.
Swine were housed in a gated pen in groups of three for
1 week of acclimation, and then separated by gated walls
(ensuring snout contact) during the following 2 weeks of
the study. All medications are listed in online supplementary table S1.
CSII catheter insertion
Animal studies took place over a period of 2–3 weeks
(1 week of acclimation week followed by 2 study weeks
2

with two to three animals studied in tandem). After
placing the animals under general anesthesia using isoflurane, commercially available CSII catheters with Teflon
cannulas were inserted into the subcutaneous tissue of
the shaved abdomen every other day for 14 days using
aseptic technique (online supplementary figures S1 and
S2). Sterile benzoin was applied to the skin surface to
enhance adhesion of the CSII catheter adhesive, sparing
the insertion site. Sufficient space was left between catheters to ensure proper excision without overlap. Both
angled and straight Teflon catheters were inserted using
the spring-loaded automated inserter. Five swine had CSII
catheters inserted at a 90° angle (Inset, Animas Corporation, West Chester, Pennsylvania, or Quickset Medtronic
MiniMed, Northridge, California; 6 mm cannula length)
and six swine at a 30° angle (Inset 30 Animas Corporation or Silhouette Paradigm Medtronic MiniMed; 13 mm
cannula length). Sterile Tegaderm adhesive bandages
were placed over the CSII catheters and infusion tubing
to secure attachment to the skin and protect from moisture/humidity during wear time. Therapeutic athletic
kinesiology tape (KT Health, Vilnius, Lithuania) was used
to cover the abdomen and provide additional protection
against catheter dislodgment due to the movement of the
animals.
Insulin infusion and BG monitoring
Each catheter was connected to an insulin pump
(OneTouch Ping, Animas Corporation or Paradigm
REAL-Time Revel, Medtronic MiniMed) stored within
a custom protective vest (Lomir Biomedical, Notre-
Dame-
de-
l’Ile-
Perrot, Quebec, Canada; online supplementary figure S2). A basal infusion of dilute Lispro/
Humulog insulin (Eli Lilly, Indianapolis, Indiana) was
continuously delivered throughout the duration of the
study at a concentration of 5 units/mL (U-5) at a rate of
0.05 units/hour. A 7-unit (70 µL) bolus was infused over
45 s before each meal to mimic the everyday use of the
pump therapy. Insulin Lispro was diluted per manufacturer’s recommendation with a sterile diluent (Eli Lilly).
BG levels were monitored with intermittent capillary BG
measurements using a commercial glucose meter and
test strips (Bayer Contour Next, Parsippany, New Jersey).
Tubing pressure recording
On the final day of the study, swine were placed under
general endotracheal anesthesia and a final 70 µL bolus
of dilute insulin and X-ray contrast agent (70% U-100
Lispro, 30% IsoVue 300) was infused. A pressure sensor
(PendoTECH, Princeton, New Jersey) was interconnected between the IIS and the pump, and connected to
a data logger (MSR Electronics, Switzerland). A custom
amplifier supplied by Capillary Biomedical was permanently attached to the pressure sensor (online supplementary figure S3). Pressure data were standardized to a
baseline of 5 s and a maximum time of 300 s (5 min). The
peak pressure (pmax) and area under the curve (AUC)
BMJ Open Diab Res Care 2019;7:e000881. doi:10.1136/bmjdrc-2019-000881

BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2019-000881 on 8 December 2019. Downloaded from http://drc.bmj.com/ on January 2, 2020 at Thomas Jefferson University.
Protected by copyright.

Clinical care education/Nutrition

were determined for each bolus data set. AUC measurements were calculated using the trapezoidal method.
Tissue excision and imaging
After 5 min of pressure recording, CSII catheters and
surrounding tissue were excised and specimens gently
frozen in isopentane cooled with dry ice (Iso-CO2) for
subsequent micro-CT imaging. Following removal of the
CSII catheter-
tissue specimens, each swine was euthanized by intravenous injection of Beuthanasia (1 mL/4.5
kg body weight) solution while under general anesthesia.
After excision, frozen CSII catheter-tissue specimens
were imaged using a micro-CT scanner (Inveon, Siemens
Medical Solutions USA, Knoxville, Tennessee) to determine the three-
dimensional (3D) distribution pattern
of insulin/X-
ray contrast agent in the subcutaneous
tissue. The surface area and volume of the insulin/
contrast agent bolus infused into the subcutaneous tissue
were measured using 3D visualization imaging software
(Amira, Thermo Fisher Scientific, Hillsboro, Oregon).
The excised tissue was then fixed, grossed, sectioned,
and stained with H&E and Masson’s trichrome stain. The
area of inflammation (Rasband, WS, ImageJ, US National
Institutes of Health, Bethesda, Maryland, 1997–2018;
https://
imagej.
nih.
gov/
ij/) and the thickness of the
inflammatory layer (Leica Biosystems, Buffalo Grove,
Illinois) were measured on all catheters with ≥35% view
of the channel (online supplementary figures S4 and
S5). The percentage of the catheter channel shown was
determined by measuring the length of the void length
and dividing it by the length of the catheter (90°=6 mm;
30°=13 mm).
Statistical analysis
Micro-CT, tissue histology, and tubing pressure data were
analyzed using analysis of variance with generalized linear
model. Kruskal-Wallis test was used for data not normally
distributed and post-hoc analyses were performed with
Bonferroni correction. Pearson correlation and linear
regression analysis were used to examine relationships
between variables of interest. A p<0.05 was set for statistical significance. Statistical analyses were performed with
SYSTAT V.13.0 and GraphPad Prism V.5.0 (GraphPad
Software, San Diego, California).
Results
The methods described above were successfully carried
out in 11 swine with no adverse events or symptomatic
hypoglycemia. We inserted a total of 48 angled and 40
straight catheters. One straight and two angled IIS were
accidentally removed and thus excluded from analysis.
Two IIS produced a pump occlusion alarm (90° inserted
for 4 days and 30° inserted for 2 days) when delivering a
bolus of insulin/X-ray contrast agent.
Tissue histology images
A total of 66 catheters were included in the analysis of
tissue histology (online supplementary tables S3 and S4).
BMJ Open Diab Res Care 2019;7:e000881. doi:10.1136/bmjdrc-2019-000881

Samples were included if the histology image showed at
least 35% of the cannula channel. The mean channel view
was 70.6% for angled and 90.1% for straight cannulas
(p<0.001).
In general, the total area of inflammation increased
consistently from day 0 to day 8 around both CSII cannula
types, then remained relatively stable from day 8 to day
14 (figure 1A). On average, the total area of inflammation was significantly larger around Teflon cannulas
inserted at 90° compared with those inserted at 30°
(p<0.001; table 1). Inflammation area was significantly
larger around 90° cannula compared with 30° cannula
on days 8–14 postinsertion (p<0.05; figure 1A).
A thick layer of inflammatory tissue (approximately
900 μm) already developed around the 90° straight
cannula after 2 days of wear time. The layer of inflammatory tissue around the 30° angled cannula was significantly
thinner after 2 days of wear time than the 90°cannula
(figure 1B; p=0.005 vs 30°). The layer of inflammatory
tissue around each Teflon cannula varied in composition,
thickness, and continuity. Inflammatory layer thickness
around the 90° cannula consistently increased from day
0 to day 10, and then stabilized through day 14. Inflammatory layer thickness around the 30° cannula increased
from day 0 to day 4, and then stabilized through day 14
(figure 1B). The layer of inflammatory tissue around the
30°cannula was significantly thinner on day 8 through
day 14 of wear time, compared with the 90° cannula.
Layer thickness around the 90° cannula was consistently
thicker compared with the 30° cannula over 2 weeks of
wear time (p<0.001; figure 1B and table 1).
Micro-CT images
Seventy-six catheters were included for micro-CT image
analysis (online supplementary table S2). Catheters were
excluded if a pump alarm occlusion occurred (n=2) or no
contrast was detected in the tissue (n=1). While studying
the first animal, micro-CT methods were developed for
all subsequent studies and thus all eight CSII catheters
from this animal were not included in the analysis.
The 70 µL bolus of insulin and X-ray contrast agent
mixed with the tissue fluid adjacent to the cannula, greatly
increasing the measured volume and surface area of the
bolus within the tissue. The average volume of a bolus of
insulin/X-ray contrast agent in the subcutaneous tissue
was three times larger than the infused 70 µL. Contrast
agent density was highest adjacent to the cannula orifice
and lowest in the tissue several millimeters away from the
orifice.
Although the pump was always set to deliver 7 units, in
four instances (5%) of all included IIS, less than 70 µL was
detected within the tissue (1× angled, 3× straight) without
an occlusion alarm. In one instance (straight, catheter
excluded from analysis), no contrast agent entered the
tissue, again without a pump occlusion alarm. Independent of wear time, a bolus of insulin/X-ray contrast agent
delivered through catheters inserted at 30° had a significantly larger mean surface area (p<0.0001) and volume
3
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Figure 1 Histopathology. (A) Area of inflammation and (B) thickness of inflammatory layer around the cannulas of CSII
catheters inserted at 30° and 90° over wear time. Values are shown as mean±SD, n=76 catheters in each group; *p<0.05
vs 30°, ANOVA-GLM. Micro-CT. (C) Bolus surface area and (D) bolus volume over catheter wear time. Values are shown as
mean±SD, n=66; *p<0.05 vs 90°, +p<0.05 vs day of insertion, ANOVA-GLM with Bonferroni correction (micro-CT image for day
0, angled CSII catheter not available). (E) Panel of representative images of tissue histology and micro-CT images of catheter-
tissue specimens for each day. Contrast agent spread in the tissue is shown in orange, and CSII catheter hub on skin surface in
teal. Trichrome stains of representative histology slides show the layer of inflammatory tissue over time around the void (white)
left by the cannula after removal. Fibrin and red blood cells are stained red; collagen/connective tissue is stained light or dark
blue. Blue and orange scale bars are equivalent to 3 mm. ANOVA-GLM, analysis of variance-generalized linear model; CSII,
continuous subcutaneous insulin infusion.

4
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Table 1 Summary of data averaged over all days
Surface area
(mm2)
Micro-CT

30°
90°

314.0+84.2
229.0+99.7

P value

Volume (mm3)

P value

SA:V (mm-1)

P value

<0.0001

198.7+66.9
145.0+65.9

0.001

1.7±0.4
1.7±1.5

1.0

Total area of inflammation
(mm2)
Histology

Tubing pressure

30°
90°

9.1±4.0
14.3±8.6

30°
90°

P value
<0.001

Thickness of layer of
inflammation (mm)
0.7±0.4
1.2±0.7

P value
<0.001

Median pmax (mm Hg/kPa)

P value

Median AUC (mm Hg/s)

P value

1176.9±828.4
2113.5±861.9

0.005

30 672.7±62 322.1
60 938.5±176 089.0

0.01

Micro-CT (n=76) and histology (n=66) values are shown as mean±SD. Tubing pressure (n=66) values are shown as median±SD.
AUC, area under the curve; pmax, peak pressure; SA:V, surface area to volume ratio.

(p=0.001) than those delivered through a 90° catheter
(table 1). There was no difference between angled and
straight CSII catheters in bolus surface area to volume
ratio.
The surface area and volume of insulin/X-ray contrast
bolus delivered into the subcutaneous tissue around both
types of CSII catheters generally decreased for several
days after insertion, then stabilized (figure 1C,D). Of
clinical interest, the surface area of the bolus delivered
through the 90° straight cannula into the subcutaneous
tissue was significantly smaller than the surface area delivered through the 30° angled cannula on day 2 and day 4
of wear time (figure 1C; p<0.05). The volume of a bolus
delivered through a straight cannula into the subcutaneous tissue was significantly smaller than the volume
delivered through an angled cannula on day 2 of wear
time (figure 1D; p<0.05). A bolus delivered through a 90°
straight cannula had a significantly smaller surface area
on days 2, 4, 10, 12, and 14 compared with the day of
insertion (figure 1C; p<0.05). The surface area of a bolus
delivered through an angled cannula was not significantly
different on all days of wear time compared with day 1,
except significantly decreased on day 4 (figure 1C). In
general, the bolus volume was higher on the day of insertion (day 0) compared with all days postinsertion when
infused through both types of CSII catheters (figure 1D).

This difference in bolus volume was statistically significant
on day 4 (90°) and day 8 (30°) versus day 1. Measured
volume was on average three times the infused volume
of 70 µL. For both catheter types, the volume and surface
area of a bolus decreased over 4 days before leveling out
at values >70 µL (figure 1D).
Twenty-four of the angled cannulas were observed to
kink (52%) within the subcutaneous tissue by micro-CT
imaging, and 13 of the straight cannulas (43%). Kinks
most commonly occurred immediately below the dermis
or just proximal to the cannula tip.
Tubing pressure
The maximum tubing pressure (pmax) as well as the area
under the pressure curve (AUC) measured over 5 min
were significantly higher for straight CSII catheters when
infusing a bolus of 70 µL (table 1). Independent of wear
time the median pmax was 44% lower in angled infusion
sets compared with straight CSII catheters (p=0.005),
while the median AUC was reduced by 50% (p=0.01).
The AUC was especially high on days 0, 2, and 4 for
straight IIS and dropped to values similar to angled IIS
after 6 days of wear time (n.s.; figure 2). It is important
to note that the SDs of pmax and AUC were quite large, as
we did not exclude extreme values from pump occlusion
alarms or leaks onto the skin (figure 2).

Figure 2 Pressure analysis. (A) Changes in maximum tubing pressure over wear time. (B) Changes in area under the pressure
curve over wear time. Values are shown as mean±SEM.
BMJ Open Diab Res Care 2019;7:e000881. doi:10.1136/bmjdrc-2019-000881
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Figure 3 Correlations. (A) Layer of inflammation versus bolus volume. (B) Layer of inflammation versus bolus surface area. (C)
Layer of inflammation versus peak tubing pressure. (D) Bolus surface area versus peak tubing pressure. *p<0.05, **p<0.005

Correlations
To better understand potential relationships among the
variables described above, we performed correlations
between the micro-CT, histology, and pressure analysis.
We found that as the thickness of the inflammatory
layer increased, the volume (p<0.05) and surface area
(p<0.005) of a bolus decreased, while pmax increased
(p<0.05; figure 3A–C). Additionally, as pmax increased, the
bolus surface area decreased (figure 3D).
Discussion
Our findings suggest that catheters inserted at a 30°
angle elicit a significantly lower inflammatory response
compared with catheters inserted at 90°. The 30° insertion angle also resulted in a greater volume and surface
area (spread) of an insulin bolus, and was associated
with lower tubing pressures compared with straight IIS.
The novelty of this work stems from the combination of
pressure analysis, micro-CT imaging, and histopathology,
giving greater insight into the mechanisms of insulin
absorption variability and other CSII therapy failure
modes.
The acute inflammatory response following CSII
cannula insertion is triggered by the initial trauma of
piercing the epidermis, dermis, and subcutaneous tissue
with a steel introducer needle and Teflon cannula.16 17
Consequently, insulin is delivered into an area of damaged
cells, connective tissue and extracellular matrix, characterized by a loss of functional capillary and lymphatic
vessels.16 Over wear time, neutrophils, macrophages, and
6

fibroblasts infiltrate the region to form a layer of acute and
chronic inflammatory tissue around the Teflon cannula
containing proteolytic enzymes.16 The accumulation of
inflammatory cells, thrombus, and fresh collagen (designated layer of inflammation) requires insulin to travel the
path of least resistance toward intact and functional capillaries and lymph vessels.12 18 A surrounding layer that is
thick, dense, and continuous will significantly hinder
the dispersion and diffusion of insulin molecules to
the surface of functional capillary and lymph vessels for
absorption into the circulation. Insulin may be degraded
within the wound or travel upward onto the skin surface
along the path of least resistance, due to a non-compliant
continuous layer of inflammatory tissue surrounding the
cannula. This concept of variable flow resistance due to
a mechanical barrier may explain the high variability
in bolus shape patterns over wear time observed in this
study (figure 1E). Our results show that with increasing
thickness of the inflammatory layer, the volume and
surface area of an insulin bolus in the subcutaneous
tissue decrease and insulin tubing pressure increases.
This may suggest that insulin flow into the adjacent tissue
is interrupted, possibly affecting glycemic control in a
real-life setting.
Independent of the cannula angle, both the inflammatory layer thickness and the area of inflammation
increased steadily over the first 4 days of wear time.
Patients are instructed to change their IIS after 2–3 days
to reduce the incident of skin irritation, poor glycemic
control, and occlusion rates, all of which increase by 40%
BMJ Open Diab Res Care 2019;7:e000881. doi:10.1136/bmjdrc-2019-000881
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by day 5.5 6 19 With increasing wear time, insulin absorption into the circulation becomes more variable and less
reliable, resulting in an incidence of unexplained hyperglycemia of up to 68% in the first 72 hours after catheter
insertion.8 20 21 Wearing the infusion set for 4 days instead
of 2 days can increase the risk of hyperglycemia by almost
40%.6
The decrease in compliant healthy tissue over wear
time may explain the rise in tubing pressure (pmax, AUC),
as insulin has increasing difficulty finding a path through
the subcutaneous tissue. Tubing pressure was decreased
by 50% using angled compared with straight CSII
catheters, suggesting an easier flow of insulin into the
surrounding tissue. Patients experience both occlusions
triggering a pump alarm and the so-called ‘silent occlusions’ in their clinical routine with a reported increase
in occlusions after 3 days of IIS use.5 22 While we only
registered two pump occlusion alarms, we saw 11 cases of
elevated pressure profiles where tubing pressure did not
return to baseline after bolus delivery but did not cause
the pump to alarm (see online supplementary material
II). In five of these instances without pump alarm, the
delivered volume was much less than the expected 70 µL
(between 0 and 50 µL). In a real-life setting, these types of
events could worsen BG control and increase the risk for
hypoglycemia and diabetic ketoacidosis (DKA).
We found a significant difference in tissue response
and insulin bolus distribution using CSII catheters of
different angles. There is limited literature on the number
of patients using an angled IIS and/or the reasons for
choosing it. Published literature on catheter angle of
insertion draws conclusions mainly from patient testimonies, case studies, and/or surveys, or does not differentiate between angles but merely cannula material.10 11 23 24
Heinemann and Krinelke25 reported in 2012 that only
about 20%–30% of patients use angled Teflon CSII catheters, while also prompting the question whether more
studies on the angle of insertion should be conducted. A
case study by Kuroda et al26 reported that patients using
angled IIS experience less unexpected hyperglycemia
and premature catheter failure. An angled CSII catheter
is less likely to hit the muscle layer, which has two advantages: first, the inflammatory response may be less severe,
and second the incidence of cannula kinking and/or
obstruction is decreased.7–9 Our results do not support
the latter as we found that more angled cannulas kinked
(52% vs 43%). This may be attributed to our method
of measuring kinks through micro-CT analysis, rather
than inspecting the cannula once it is already removed.
In summary, our results showed that angled CSII catheters were associated with a lower inflammatory tissue
response and lower tubing pressures. Both bolus surface
area and volume were significantly larger when infused
through angled IIS, suggesting an increased contact of
insulin with capillaries and lymph vessels.
While our findings were significant, there are limitations to our methods and analysis. First, the histology
images used for analysis were produced from a thin film
BMJ Open Diab Res Care 2019;7:e000881. doi:10.1136/bmjdrc-2019-000881

of tissue (2–5 µm), thus only providing a snapshot of the
inflammatory response to the cannula of a CSII catheter.
Second, locating an angled insertion channel in a fatty
tissue specimen is methodologically more challenging
than for straight catheters. To account for this limitation,
we only included images showing at least 35% of the
insertion channel and created four standardized points
to measure the thickness of layer of the inflammatory
tissue, measured independently by two investigators. We
expected the total area of inflammation to remain similar
regardless of the channel view and found this to be true
for a data subset (results not shown). Third, micro-CT
imaging was performed on frozen tissue samples to
preserve the shape of the bolus, but freezing the specimen affects the structure of the subcutaneous tissue
and may cause artifacts. Others, however, have successfully employed similar methods to analyze insulin bolus
shape and distribution in the subcutaneous tissue.27 28
In order to better understand how insulin distribution,
inflammation and pressure influence insulin absorption,
future studies should include insulin pharmacokinetic
clamp experiments. The set-up presented here required
large amounts of skin and subcutaneous tissue, ruling out
a human study. Although the outcome may not be the
same as in a patient with diabetes, swine skin and subcutaneous tissue are similar to human tissue in their structure
and wound healing pattern.14 15
The CSII catheter is considered the weak link of insulin
pump therapy, often failing to ensure reliable dose-to-
dose or day-to-day insulin delivery/absorption, leading to
clinical complications such as hypoglycemia and hyperglycemia or DKA.25 Our results show that even when the
pump fails to deliver a full bolus into the subcutaneous
tissue, it will sometimes fail to alarm, and the same holds
true for unusually high tubing backpressures. Unreliable
insulin delivery may cause clinical problems in the daily
therapy of an insulin-dependent patient. We furthermore
show that after approximately 6 days of wear time, the
inflammatory tissue response to a Teflon cannula stabilizes. This suggests that the wear time of a CSII catheter may be prolonged by overcoming the initial acute
inflammatory response and thus the associated variability
in insulin absorption. To our knowledge, this is the first
systematic study assessing tissue response, bolus distribution and tubing pressure of commercially available
angled and straight Teflon CSII catheters and the first
to correlate these findings over CSII catheter wear time.
Based on our findings, we believe that in future studies,
CSII catheters should not only be grouped by material but also separated by angle of insertion, in order
to adequately drive future IIS recommendations. The
methods and results presented here may assist in the
design of future studies to develop an ideal IIS with reliable dose-to-dose and day-to-day delivery and absorption
of insulin over an extended duration of wear time.
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